AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

KOL Perspectives of Adaptive Trial Designs in IBD, 2018 Study - ResearchAndMarkets.com

February 22, 2019

DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “KOL Perspectives: Adaptive Trial Designs in IBD” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD.

Questions topics

Key Highlights

Scope

In total, we conducted interviews with 10 KOLs -

KOL data is analyzed to produce -

Reasons to Buy

Key Topics Covered:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/x4jwc4/kol_perspectives?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005114/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/22/2019 03:58 AM/DISC: 02/22/2019 03:58 AM

http://www.businesswire.com/news/home/20190222005114/en